Janus Henderson Group PLC Has $53.06 Million Stock Holdings in Heartflow, Inc. $HTFL

Janus Henderson Group PLC grew its position in shares of Heartflow, Inc. (NASDAQ:HTFL) by 152.0% in the 1st quarter, HoldingsChannel reports. The fund owned 2,180,976 shares of the company’s stock after buying an additional 1,315,416 shares during the period. Janus Henderson Group PLC’s holdings in Heartflow were worth $53,063,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in HTFL. Vanguard Group Inc. purchased a new stake in shares of Heartflow in the third quarter worth approximately $48,871,000. Legal & General Group Plc bought a new position in Heartflow during the third quarter valued at about $59,000. Franklin Resources Inc. purchased a new stake in shares of Heartflow during the 3rd quarter worth approximately $10,829,000. UBS Group AG bought a new stake in Heartflow in the 3rd quarter valued at about $5,130,000. Finally, Sei Investments Co. bought a new stake in Heartflow during the 3rd quarter valued at $303,000.

Heartflow Stock Performance

Shares of Heartflow stock opened at $25.23 on Friday. The stock has a market capitalization of $2.18 billion and a PE ratio of -8.11. Heartflow, Inc. has a 52-week low of $20.13 and a 52-week high of $41.22. The company has a 50-day simple moving average of $29.02 and a two-hundred day simple moving average of $28.10.

Heartflow (NASDAQ:HTFL) last posted its earnings results on Thursday, May 14th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.08. The business had revenue of $52.59 million during the quarter. Heartflow’s revenue for the quarter was up 41.3% on a year-over-year basis. As a group, equities research analysts forecast that Heartflow, Inc. will post -0.82 EPS for the current fiscal year.

Insider Activity

In related news, insider Campbell Rogers sold 9,219 shares of the stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $28.34, for a total transaction of $261,266.46. Following the transaction, the insider owned 78,731 shares in the company, valued at $2,231,236.54. This represents a 10.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John C.M. Farquhar sold 22,562 shares of the firm’s stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $27.75, for a total transaction of $626,095.50. Following the completion of the sale, the chief executive officer owned 435,373 shares in the company, valued at $12,081,600.75. This represents a 4.93% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 115,805 shares of company stock valued at $3,548,884 over the last quarter. 7.70% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on HTFL shares. Piper Sandler reiterated an “overweight” rating on shares of Heartflow in a research report on Thursday, June 11th. Wells Fargo & Company upped their price target on shares of Heartflow from $35.00 to $37.00 and gave the company an “overweight” rating in a report on Friday, May 15th. Stifel Nicolaus set a $40.00 price objective on Heartflow in a research report on Wednesday, July 15th. Robert W. Baird assumed coverage on shares of Heartflow in a research note on Friday. They set an “outperform” rating and a $34.00 target price on the stock. Finally, Canaccord Genuity Group dropped their price target on Heartflow from $43.00 to $37.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Heartflow has a consensus rating of “Moderate Buy” and an average price target of $36.57.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.